LitAlert ~~ GeneLit.com

    • FDA Approves Lynparza With Myriad, Foundation Med CDx Tests in HRR-Mutated Prostate Cancer
    • [No author given]
    • GenomeWeb. 2020 May 20.
    • Comparison of mutation profile between primary phyllodes tumors of the breast and their paired local recurrences.
    • Mitus J, Adamczyk A, Majchrzyk K, Kowalik A, Rys J, Niemiec J.
    • Pol J Pathol. 2020 May 20;71(1):7-12. doi: 10.5114/pjp.2020.94899.
    • First PARP Inhibitor Approved for Metastatic Prostate Cancer.
    • Nelson R.
    • Medscape. 2020 May 19.
    • Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer.
    • Brönimann S, Lemberger U, Bruchbacher A, Shariat SF, Hassler MR.
    • Curr Opin Urol. 2020 May 13. doi: 10.1097/MOU.0000000000000776. Epub ahead of print.
    • Review
    • Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers.
    • Liptay M, Barbosa JS, Rottenberg S.
    • Front Oncol. 2020 May 5;10:670. doi: 10.3389/fonc.2020.00670.